91![12th Invitation to manufacturers and suppliers of medicinal products for HIV infection and related diseases, including treatment for hepatitis B and C, to submit an Expression of Interest (EOI) for product evaluation to 12th Invitation to manufacturers and suppliers of medicinal products for HIV infection and related diseases, including treatment for hepatitis B and C, to submit an Expression of Interest (EOI) for product evaluation to](https://www.pdfsearch.io/img/c355b7eab8bde9fcf46e7d44521af2fc.jpg) | Add to Reading ListSource URL: apps.who.intLanguage: English - Date: 2014-09-18 04:42:10
|
---|
92![SOGC CLINICAL PRACTICE GUIDELINE No. 310, August 2014 Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission SOGC CLINICAL PRACTICE GUIDELINE No. 310, August 2014 Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission](https://www.pdfsearch.io/img/f60f51315b46caf878ebb88d84aa2d29.jpg) | Add to Reading ListSource URL: sogc.orgLanguage: English - Date: 2014-09-25 08:34:19
|
---|
93![FDA Patient Safety News: Show #38, April 2005 FDA Patient Safety News: Show #38, April 2005](https://www.pdfsearch.io/img/1dd28d161d0f955a2197351e6531caca.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
94![Microsoft Word[removed]Adult ART Guidelines Microsoft Word[removed]Adult ART Guidelines](https://www.pdfsearch.io/img/54d023213d65883e8f1d6ae5c44ffc14.jpg) | Add to Reading ListSource URL: www.fidssa.co.zaLanguage: English - Date: 2010-09-29 05:18:06
|
---|
95![1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INTELENCE® safely and effectively. See full prescribing information for INTELENCE®. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INTELENCE® safely and effectively. See full prescribing information for INTELENCE®.](https://www.pdfsearch.io/img/99bb796628be257befc27d745f7b7f05.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2014-08-21 15:16:08
|
---|
96![) . ., RCG Analysis – CNAA2007 Resistance ) . ., RCG Analysis – CNAA2007 Resistance](https://www.pdfsearch.io/img/0823d44064bcc385e9581912486f73a2.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 1999-10-29 04:20:02
|
---|
97![HIV/AIDS / Cyclopropanes / Purines / Non-nucleoside reverse transcriptase inhibitors / Lactams / Nevirapine / Zidovudine / Antiretroviral drug / HIV / Medicine / Health / Chemistry HIV/AIDS / Cyclopropanes / Purines / Non-nucleoside reverse transcriptase inhibitors / Lactams / Nevirapine / Zidovudine / Antiretroviral drug / HIV / Medicine / Health / Chemistry](/pdf-icon.png) | Add to Reading ListSource URL: www.fda.govLanguage: English - Date: 1999-10-27 10:32:13
|
---|
98![](https://www.pdfsearch.io/img/e568a5d39efe65bae0137e493c5012bf.jpg) | Add to Reading ListSource URL: media.wiley.comLanguage: English - Date: 2013-08-22 16:17:40
|
---|
99![V Contents List of Contributors XIII Preface XVII A Personal Foreword XIX V Contents List of Contributors XIII Preface XVII A Personal Foreword XIX](https://www.pdfsearch.io/img/7e912ee0829b9b29619956cb3d00fbe9.jpg) | Add to Reading ListSource URL: www.wiley-vch.deLanguage: English - Date: 2009-12-13 21:03:07
|
---|
100![HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------DOSAGE FORMS AND STRENGTHS--------------------• Tablet: 600-mg tablets supplied in 30-count bottles[removed]These highlights do not include all the informati HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------DOSAGE FORMS AND STRENGTHS--------------------• Tablet: 600-mg tablets supplied in 30-count bottles[removed]These highlights do not include all the informati](https://www.pdfsearch.io/img/a8b33facecd687aedbe2b0a4e579024d.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2009-03-31 14:51:21
|
---|